These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15549345)

  • 41. Patient-based and clinician-based support for the remission criteria in schizophrenia.
    Docherty JP; Bossie CA; Lachaux B; Bouhours P; Zhu Y; Lasser R; Gharabawi GM
    Int Clin Psychopharmacol; 2007 Jan; 22(1):51-5. PubMed ID: 17159460
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
    Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Results of a multicenter AMDP study with fluperlapine in schizophrenic patients.
    Woggon B; Heinrich K; Küfferle B; Müller-Oerlinghausen B; Pöldinger W; Rüther E; Schied HW
    Arzneimittelforschung; 1984; 34(1A):122-4. PubMed ID: 6145427
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Changes in positive and negative symptoms, general psychopathology in schizophrenic patients during augmentation of antipsychotics with glycine: a preliminary 10-week open-label study].
    Strzelecki D; Rabe-Jabłońska J
    Psychiatr Pol; 2011; 45(6):825-37. PubMed ID: 22335126
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment.
    Li M; Chen Z; Deng W; He Z; Wang Q; Jiang L; Ma X; Wang Y; Chua SE; Cheung C; McAlonan GM; Sham PC; Collier DA; Gong Q; Li T
    Psychol Med; 2012 Jul; 42(7):1475-83. PubMed ID: 22030695
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Efficacy and tolerability of quetiapine in hospitalised schizophrenic patients during the acute treatment phase: a PMS study].
    Leweke FM; Gerth CW; Koethe D; Nolden BM; Klosterkötter J
    Fortschr Neurol Psychiatr; 2007 Apr; 75(4):211-9. PubMed ID: 17230308
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
    Akhondzadeh S; Safarcherati A; Amini H
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Examining the validity of DSM-III-R schizoaffective disorder and its putative subtypes in the Roscommon Family Study.
    Kendler KS; McGuire M; Gruenberg AM; Walsh D
    Am J Psychiatry; 1995 May; 152(5):755-64. PubMed ID: 7726316
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study.
    Schennach-Wolff R; Obermeier M; Seemüller F; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Engel RR; Möller HJ; Riedel M
    J Clin Psychopharmacol; 2010 Dec; 30(6):726-31. PubMed ID: 21105273
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Why do indiviuals with schizophrenia drop out of observational clinical trials?
    Hofer A; Radner V; Edlinger M; Kemmler G; Rettenbacher MA; Fleischhacker WW
    Psychiatry Res; 2017 Oct; 256():1-5. PubMed ID: 28609646
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Participation in clinical trials may improve care of acute schizophrenia inpatients in a general hospital.
    Halbreich U; Smail N; Tu X; Halbreich J
    CNS Spectr; 2008 Sep; 13(9):757-61. PubMed ID: 18849894
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative study of four evaluation criteria in a clinical trial with schizophrenic patients.
    Fombonne E; Peron-Magnan P; Fuhrer R; Simon P
    Neuropsychobiology; 1986; 16(4):186-92. PubMed ID: 2886952
    [TBL] [Abstract][Full Text] [Related]  

  • 54. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?
    Kemp AS; Schooler NR; Kalali AH; Alphs L; Anand R; Awad G; Davidson M; Dubé S; Ereshefsky L; Gharabawi G; Leon AC; Lepine JP; Potkin SG; Vermeulen A
    Schizophr Bull; 2010 May; 36(3):504-9. PubMed ID: 18723840
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: comparison of psychopathological and psychosocial course and outcome and prediction of chronicity.
    Möller HJ; Jäger M; Riedel M; Obermeier M; Strauss A; Bottlender R
    Eur Arch Psychiatry Clin Neurosci; 2010 Aug; 260(5):367-84. PubMed ID: 20495979
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selection bias in clinical trials with antipsychotics.
    Hofer A; Hummer M; Huber R; Kurz M; Walch T; Fleischhacker WW
    J Clin Psychopharmacol; 2000 Dec; 20(6):699-702. PubMed ID: 11106145
    [TBL] [Abstract][Full Text] [Related]  

  • 57. AMDP psychopathology factors in chronic schizophrenia: a clinical trial of two long-acting neuroleptics.
    Lapierre YD; von Frenckell R
    Mod Probl Pharmacopsychiatry; 1983; 20():193-203. PubMed ID: 6137766
    [No Abstract]   [Full Text] [Related]  

  • 58. Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms?
    Lindamer LA; Buse DC; Lohr JB; Jeste DV
    Biol Psychiatry; 2001 Jan; 49(1):47-51. PubMed ID: 11163779
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationship between crossover and modality shift effects in sequential reaction time performance of schizophrenic patients.
    Jahn T; Rey ER
    Eur Arch Psychiatry Clin Neurosci; 1993; 243(3-4):199-204. PubMed ID: 7906955
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Deliverability of psychoeducational family management.
    Wiedemann G; Hahlweg K; Hank G; Feinstein E; Müller U; Dose M
    Schizophr Bull; 1994; 20(3):547-56. PubMed ID: 7973470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.